Quanterix Corporation (QTRX)

NASDAQ: QTRX · IEX Real-Time Price · USD
15.60
-0.19 (-1.20%)
Apr 19, 2024, 3:28 PM EDT - Market open
-1.20%
Market Cap 597.80M
Revenue (ttm) 122.37M
Net Income (ttm) -32.33M
Shares Out 38.25M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 211,024
Open 15.73
Previous Close 15.79
Day's Range 15.58 - 16.33
52-Week Range 11.39 - 29.70
Beta 1.33
Analysts Strong Buy
Price Target 32.67 (+109.42%)
Earnings Date May 7, 2024

About QTRX

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of ... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Dec 7, 2017
Employees 441
Stock Exchange NASDAQ
Ticker Symbol QTRX
Full Company Profile

Financial Performance

In 2023, Quanterix's revenue was $122.37 million, an increase of 15.96% compared to the previous year's $105.52 million. Losses were -$32.33 million, -66.56% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for QTRX stock is "Strong Buy." The 12-month stock price forecast is $32.67, which is an increase of 109.42% from the latest price.

Price Target
$32.67
(109.42% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership...

4 weeks ago - Business Wire

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phosph...

6 weeks ago - Business Wire

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fo...

7 weeks ago - Business Wire

Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, ...

7 weeks ago - Business Wire

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer's Disease

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaboratio...

7 weeks ago - Business Wire

Quanterix to Present at Cowen's 44th Annual Health Care Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...

7 weeks ago - Business Wire

Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference ca...

2 months ago - Business Wire

Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe...

4 months ago - Business Wire

Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe...

5 months ago - Business Wire

Quanterix Releases Operating Results for Third Quarter 2023

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation today announced financial results for the three months ended September 30, 2023.

5 months ago - Business Wire

Quanterix Releases Operating Results for Third Quarter 202

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation today announced financial results for the three months ended September 30, 2023.

5 months ago - Business Wire

Quanterix to Report Third Quarter 2023 Financial Results on November 7, 2023

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financia...

6 months ago - Business Wire

Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high a...

6 months ago - Business Wire

Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced the signing of a licen...

6 months ago - Business Wire

Quanterix CEO to Speak at Goldman Sachs Alzheimer's Disease Day

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...

7 months ago - Business Wire

Quanterix to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...

8 months ago - Business Wire

William P. Donnelly Appointed to Quanterix's Board of Directors

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced...

8 months ago - Business Wire

Quanterix Appoints Vandana Sriram as Chief Financial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced...

9 months ago - Business Wire

Quanterix Releases Operating Results for Second Quarter 2023

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the th...

9 months ago - Business Wire

Quanterix to Present at Canaccord Genuity 43rd Annual Growth Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...

9 months ago - Business Wire

Quanterix's Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced...

9 months ago - Business Wire

Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financia...

9 months ago - Business Wire

Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced...

10 months ago - Business Wire

Quanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer...

11 months ago - Business Wire

Quanterix Releases Operating Results for First Quarter 2023

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the th...

1 year ago - Business Wire